Asia Fresh News

Asia Fresh Stories

Archive for May 29th, 2014

Synergy 3 Command and Control Platform Rolled out by Synectics

leave a comment »

SHEFFIELD, England, May 28, 2014 /PRNewswire/ —

Synectics has announced the wide-scale roll-out of its evolved Synergy 3 command and control platform, following a global series of successful preview sessions.

Synergy 3 is a flexible, open platform that enables alarms and events, security and process control sub-systems, video, and data to be monitored, managed, and recorded from a single unified interface.

The latest evolution of Synectics’ field-proven technology, Synergy 3 is simple to deploy and integrate and features new functionality including a fully customisable user interface, incident collaboration tools, and interactive mapping engine with Geospatial Information System (GIS) technology.

David Aindow, Product & Technology Director with Synectics, said: “Synergy 3 really has been ‘developed by experience’. We’ve distilled all we have learned over 25 years, feedback from our customers and analysis of future market trends, and channelled that knowledge into a platform that is flexible, scalable and obsolescence-proof.

“From enhanced workflow functionality to guide operators seamlessly and efficiently through required procedures and responses to alarm events to improved reporting capabilities, we’ve looked closely at how to evolve a known and trusted solution to improve user experience in practical ways.”

Synergy 3 offers a flexible, tiered software licensing structure that allows users to select the right functionality to meet their needs according to scale and complexity. With multiple site federation, full peer to peer, or master to slave, command and control and uncapped scalability to accommodate system growth, Synergy 3 is the ideal solution for any application.

Paul Webb, Managing Director, Synectic Systems, said: “From small companies to enterprise-scale operators, whether in public space, oil and gas, marine, gaming or any other security-critical sectors, the latest evolution of Synergy is so flexible that it can meet very specific needs, enabling businesses to grow their surveillance solution in-step with organic expansion.

“Our roll-out of Synergy 3 follows very positive feedback from a series of previews at high profile security shows and we look forward to engaging further with our customers at events such as IFSEC to demonstrate the business benefits that the latest evolution of Synergy delivers.”

Further updates on Synergy 3 can be found at http://www.synecticsglobal.com or via @synecticsglobal on Twitter.

Source: Synectics

Written by asiafreshnews

May 29, 2014 at 11:51 pm

Posted in Uncategorized

Revolutionary Urban Wind Turbine

leave a comment »

ROTTERDAM, Netherlands, May 27, 2014 /PRNewswire/ — The Rotterdam based research and development company “The Archimedes” reveals that it has developed a totally new generation of wind turbines for domestic use. This wind turbine will gain much more energy out of the wind than current generation wind turbines. Additionally this so-called Liam F1 Urban Wind Turbine hardly produces sound because of its remarkable design. The turbine will be presented to the press and people coming from over 40 countries on Tuesday.

(Photo: http://photos.prnewswire.com/prnh/20140527/689219-a )
(Photo: http://photos.prnewswire.com/prnh/20140527/689219-b )

The Liam F1 generates an average of 1,500 kilowatt-hour of energy at a wind-speed of 5m/s, which resembles half of the power consumption of a common household. In combination with solar-panels on the roof, a household could be totally self-supporting for its own energy needs. Engineer Richard Ruijtenbeek from The Archimedes explains that “when there is wind you use the energy produced by the wind turbine, when the sun is shining you use the solar cells to produce the energy.”

At present there are very few wind turbines in use for generating energy in households. One of the reasons for his is that the yield from current generation wind turbines is very low (average of 25 percent), and that the blades produce too much noise. This is where the inventor of the Archimedes wind turbine, Marinus Mieremet, has adjusted the design. By combining the form of the Nautilus shell, the theoretics of Archimedes and his own mathematics, he created a new turbine that hardly has any resistance and has resulted in a design that is virtually soundless.

Because of its screw-form, the Liam will automatically aim to the optimal position of the wind, just like a pennant and will therefore have a maximum yield. According to Mieremet the yield is 80 percent of the maximum that is theoretically feasible. The Liam has been tested over 50 times because initially the developers couldn’t believe the results they saw.

Although the revealing of the method and unveiling of the wind turbine will take place today, the company has already sold 7,000 turbines in 14 countries. The interest is so big that the company has started developing relatively small turbines for use on boats, on lampposts and in water.

Source: The Archimedes

Written by asiafreshnews

May 29, 2014 at 11:43 pm

Posted in Uncategorized

Sanofi and Lilly announce licensing agreement for Cialis(R) (tadalafil) OTC

leave a comment »

— Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents

PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).

Under the terms of the agreement, Sanofi acquires the exclusive rights to apply for approval of Cialis OTC in the United States, Europe, Canada and Australia. Sanofi also holds exclusive rights to market Cialis OTC following Sanofi’s receipt of all necessary regulatory approvals. If approved, Sanofi anticipates providing Cialis OTC after expiration of certain patents. Terms of the licensing agreement were not disclosed.

“This agreement provides us with an opportunity to work with Lilly, a leader in men’s health, to transform how this important medicine is offered to millions of men throughout the world,” said Vincent Warnery, senior vice president, Global Consumer Healthcare Division, Sanofi. “The opportunity to forge an industry-leading partnership that adds to Sanofi Consumer Healthcare’s leading portfolio and successful track record of over-the-counter switches reinforces consumer health care as a major growth platform for Sanofi.”

“Millions of men worldwide trust Cialis to treat ED. We are pleased to work with Sanofi to pursue a path that could allow more men who suffer from ED to obtain convenient access to a safe and reliable product without a prescription,” said David Ricks, senior vice president, Lilly, and president, Lilly Bio-Medicines. “Switching a medicine to over-the-counter is a highly regulated process that is data-driven and scientifically rigorous. Together with Sanofi, we look forward to working closely with regulatory authorities to define the proper actions and necessary precautions to help patients use over-the-counter Cialis appropriately.”

Cialis was first approved by the European Medicines Agency in 2002, then by the U.S. Food and Drug Administration in 2003, for the treatment of erectile dysfunction. Ultimately, Cialis has received approval in more than 120 countries for indications that vary by country, including erectile dysfunction and erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (BPH). Cialis reached $2.16 billion USD (EUR 1.58 billion) in worldwide sales in 2013 and has recorded total global sales of more than $14 billion USD (EUR 10.2 billion) since launch. To date, more than 45 million men worldwide have been treated with Cialis.

About Cialis

Currently only available with a prescription, Cialis is a tablet taken to treat erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and symptoms of BPH. Cialis is the only PDE-5 inhibitor treatment that offers men a choice when it comes to treatment for erectile dysfunction – Cialis for use as needed and Cialis for once daily use. To learn more about Cialis, visit www.cialis.com.

Cialis is not for women or children. It is important to note that Cialis is not to be taken with medicines called “nitrates” such as isosorbide dinitrate or isosorbide mononitrate which are often prescribed for chest pain; or with recreational drugs called “poppers” like amyl or butyl nitrite, as the combination may cause an unsafe drop in blood pressure; or if allergic to Cialis or Adcirca® (tadalafil), or any of its ingredients. Anyone who experiences any symptoms of an allergic reaction, such as rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing, should call a healthcare provider or get help right away.

About Erectile Dysfunction (ED)

ED is a medical condition in which a man has trouble getting or keeping an erection. It is very common: more than half of men over 40 years old have ED.[i]

About Sanofi Consumer Healthcare

Sanofi Consumer Healthcare is committed to providing consumers around the world with self-care solutions that empower them to better manage their health and well-being through leading brands in the areas of Allergy, Digestive health, Feminine care, Cough, cold, flu & sinus and Vitamins, minerals & supplements. We place people at the very heart of everything we do and strive to identify and fulfil their needs by delivering consumer insights-driven innovation, leveraging our medical & scientific heritage and our close collaboration with healthcare professionals, easing consumer access via switching relevant prescription medicines to over-the-counter solutions and applying the pharmaceutical quality standards delivered by our Group’s global manufacturing network. In 2013, Sanofi Consumer healthcare achieved a EUR 3.0 billion ($4.1 billion USD) turnover representing a 5.2% growth vs. 2012 (constant exchange rates) and ranked #3 worldwide consumer healthcare player (Nicholas Hall- 2013).

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). To learn more about Sanofi, please visit us at www.sanofi.com.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

Indications

Cialis is available via prescription only and is approved to treat erectile dysfunction, or ED (2.5 mg, 5 mg, 10 mg, 20 mg), and both ED and the signs and symptoms of benign prostatic hyperplasia, or BPH (5 mg). Taking Cialis with finasteride when starting BPH treatment has been studied for 26 weeks. Cialis is not for women or children.

Important Safety Information for CIALIS® (tadalafil) tablets
What Is The Most Important Information I Should Know About CIALIS?
Do not take CIALIS if you:

  • take medicines called “nitrates” such as isosorbide dinitrate or isosorbide mononitrate which are often prescribed for chest pain as the combination may cause an unsafe drop in blood pressure
  • use recreational drugs called “poppers” like amyl nitrite and butyl nitrite
  • are allergic to CIALIS or ADCIRCA® (tadalafil), or any of its ingredients. Call your healthcare provider or get help right away if you experience any symptoms of an allergic reaction, such as rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing

After taking a single tablet, some of the active ingredient of CIALIS remains in your body for more than 2 days. The active ingredient can remain longer if you have problems with your kidneys or liver, or you are taking certain other medications.
Stop sexual activity and get medical help right away if you get symptoms such as chest pain, dizziness, or nausea during sex. Sexual activity can put an extra strain on your heart, especially if your heart is already weak from a heart attack or heart disease.

What Should I Tell My Healthcare Provider Before Taking CIALIS?
CIALIS is not right for everyone. Only your healthcare provider and you can decide if CIALIS is right for you.
Ask your healthcare provider if your heart is healthy enough for you to have sexual activity. You should not take CIALIS if your healthcare provider has told you not to have sexual activity because of your health problems. Before taking CIALIS, tell your healthcare provider about all your medical problems, particularly if you have or ever had:

  • heart problems such as chest pain (angina), heart failure, irregular heartbeats, or have had a heart attack
  • high or low blood pressure or have high blood pressure that is not controlled
  • stroke
  • liver or kidney problems or require dialysis
  • retinitis pigmentosa, a rare genetic (runs in families) eye disease
  • severe vision loss, including a condition called NAION
  • stomach ulcers or a bleeding problem
  • a deformed penis shape or Peyronie’s disease
  • an erection that lasted more than 4 hours
  • blood cell problems such as sickle cell anemia, multiple myeloma, or leukemia

Can Other Medicines Affect CIALIS?
Tell your healthcare provider about all the medicines you take especially if you take:

  • medicines called “nitrates” which are often prescribed for chest pain
  • alpha-blockers often prescribed for prostate problems
  • blood pressure medications
  • medicines for HIV or some types of oral antifungal medications
  • some types of antibiotics such as clarithromycin, telithromycin, erythromycin (several brand names exist, please contact your healthcare provider to determine if you are taking this medicine)
  • other medicines or treatments for erectile dysfunction (ED)
  • CIALIS is also marketed as ADCIRCA for the treatment of pulmonary arterial hypertension. Do not take both CIALIS and ADCIRCA. Do not take sildenafil citrate (Revatio®)* with CIALIS.

What Should I Avoid While Taking CIALIS?

  • Do not use other ED medicines or ED treatments while taking CIALIS.
  • Do not drink too much alcohol when taking CIALIS (for example, 5 glasses of wine or 5 shots of whiskey). Drinking too much alcohol can increase your chances of getting a headache or getting dizzy, increasing your heart rate, or lowering your blood pressure.

What Are The Possible Side Effects Of CIALIS?
The most common side effects with CIALIS are:
headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects usually go away after a few hours. Men who get back pain and muscle aches usually get it 12 to 24 hours after taking CIALIS. Back pain and muscle aches usually go away within 2 days. Call your healthcare provider if you get any side effect that bothers you or one that does not go away.

Uncommon but serious side effects include:
An erection that won’t go away: If you get an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.

In rare instances, men taking prescription ED tablets, including CIALIS, reported a sudden decrease or loss of vision or hearing (sometimes with ringing in the ears and dizziness). It’s not possible to determine if these events are related directly to the ED tablets or to other factors. If you have a sudden decrease or loss of vision or hearing, stop taking any ED tablet, including CIALIS and call a healthcare provider right away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
CIALIS does not:

  • cure ED
  • increase a man’s sexual desire
  • protect a man or his partner from sexually transmitted diseases, including HIV
  • serve as a male form of birth control

CIALIS is available by prescription only. For additional information, talk to your healthcare provider and please see the Full Prescribing Information, and Medication Guide. You may also learn more about Cialis at www.cialis.com.

* The brand listed is a trademark of its respective owner and is not a trademark of Eli Lilly and Company. The maker of this brand is not affiliated with and does not endorse Eli Lilly and Company or its products.

P-LLY

TD Con-F ISI 03FEB2012

TD91306

[i] Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s and Lilly’s management believe that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the companies, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In particular, there are no guarantees that regulatory authorities will approve Cialis for nonprescription use. Risks and uncertainties also include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Companies’ ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013, and in the public filings with the SEC made by Lilly, including those listed under “risk Factors” in Lilly’s annual report on Form 10-K for the year ended December 31, 2013. Other than as required by applicable law, the companies do not undertake any obligation to update or revise any forward-looking information or statements.

 

Contacts:   
   
Corporate Media Relations  Investor Relations 
Jack Cox, Sanofi Sebastien Martel, Sanofi
Tel.: +33-1-53-77-46-46 Tel.: +33-1-53-77-45-45
jack.cox@sanofi.com  ir@sanofi.com 
   
Celeste Stanley, Lilly Phil Johnson, Lilly
Tel.: +1-317-626-8896 Tel.: +1-317-655-6874
celeste_stanley@lilly.com  johnson_philip_l@lilly.com 

Logo – http://photos.prnewswire.com/prnh/20031219/LLYLOGO
Logo – http://photos.prnewswire.com/prnh/20140527/91338

Source: Eli Lilly and Company

Written by asiafreshnews

May 29, 2014 at 11:22 pm

Posted in Uncategorized

Fi Vietnam — Successful Debut

leave a comment »

HO CHI MINH CITY, Vietnam, May 28, 2014 /PRNewswire/ — The recent launch of Food Ingredients (Fi) Vietnam, the latest event from organiser UBM’s global Fi brand was a great success according to UBM Asia (Thailand) Business Director, Rungphech (Rose) Chitanuwat. The focus of all three days was providing the right ingredients for success – business, networking and learning. Unlike other events, Fi is dedicated exclusively to food ingredients — not finished foods. This focus ensures that we meet the needs of F&B industry professionals at all levels of the supply chain.

Crowded visitors in the exhibition hall, Fi Vietnam 2015
Crowded visitors in the exhibition hall, Fi Vietnam 2015

 

Crowded visitors in the exhibition hall, Fi Vietnam 2015
Crowded visitors in the exhibition hall, Fi Vietnam 2015

“Fi Vietnam undoubtedly answered an industry need, providing a huge benefit to visitors as well as exhibitors”, she said. “There was overwhelming positive feedback from exhibitors and visitors alike. Exhibitors reported that they were pleased with the quantity and quality of visitors and was an excellent opportunity to further develop their business. Kerry Vietnam General Manager Mervyn Gribben said “Vietnam is a vibrant market with a mix of traditional and new food ingredients. Fi Vietnam 2014 was a very useful event to reach out to existing and potential customers. We’re very excited to be a part of it and will definitely come back.”

The large number of international exhibitors and visitors, coming from 16 countries testified to the growing interest in the Vietnamese F&B sector. Visitors clearly appreciated the opportunity to meet local, regional and international exhibitors all in one place at one time and attend the event conference and exhibitor seminars that augmented the tradeshow.

Rungphech expressed her sincere appreciation to Fi Vietnam’s partners the Vietnam Association of Food Science and Technology, the Food and Foodstuff Association of Ho Chi Minh City, and the Vietnam Chamber of Commerce and Industry, and also the distinguished conference and seminar speakers for their outstanding support which made Fi Vietnam 2014 a resounding hit.

“The success was such that many exhibitors have already rebooked for next year, while many new exhibitors have expressed strong interest in attending.  We look forward to building on the success of this year’s premier event and welcoming F&B professionals to Fi Vietnam 2015 on 20 — 22 May at the Saigon Exhibition and Convention Centre”, Rungphech concluded.

About The Organiser

UBM Asia, the leading organiser of exhibitions in Asia. Owned by UBM plc which is listed on the London Stock Exchange, UBM Asia operates in 19 market sectors with headquarters in Hong Kong and subsidiary companies across Asia, including UBM China in Shanghai, Hangzhou, Guangzhou and Beijing. We have over 240 products including trade fairs, conferences, trade publications, B2B/B2C portals and virtual event services. As Asia’s leading exhibition organiser and the biggest commercial organiser in China, India and Malaysia, we stage the leading events of their kind across the region. Our 200 events, 24 publications and 16 vertical portals serve over 1,000,000 quality exhibitors, visitors, conference delegates, advertisers and subscribers from all over the world with high value face-to-face business-matching events, quality and instant market news and industry trends, and round-the-clock online trading networks and sourcing platforms. We have over 1,100 staff in 21 major cities across Asia.

UBM Asia in ASEAN

In ASEAN, we serve 13 market sectors with wholly-owned subsidiary companies and JV companies in seven offices in the major cities in ASEAN, including Bangkok, Hanoi, Ho Chi Minh City, Jakarta, Kuala Lumpur, Manila and Singapore. We provide over 60 products in various categories: trade fairs, conferences and publications. As the leading B2B event organiser in the region, we are the largest exhibition organiser in Malaysia.

Our products serve tens of thousands of exhibitors, visitors, conference delegates, advertisers, subscribers and corporations in the region and from all over the world with high value face-to-face business-matching events and quality conference programmes presented by top-notch industry leaders. We have over 130 staff in six countries.

Source: UBM Asia (Thailand)

Written by asiafreshnews

May 29, 2014 at 11:05 pm

Posted in Uncategorized

Cosmoprof Asia Launches New Initiatives — Spot On Beauty and Boutique

leave a comment »

HONG KONG, May 27, 2014 /PRNewswire/ — Cosmoprof Asia, the definitive beauty trade event in the Asia Pacific region, is set to open with a diverse range of exhibitors this November. The last edition registered impressive figures: 2,168 exhibitors from 43 countries and regions (10% up on 2012); 76,200 sqm in exhibition space; 60,985 visitors (10% up on 2012) from 125 countries and regions of which 37,575 came from overseas and 345 trade journalists.

Cosmoprof Asia 2014 launches the SPOT ON BEAUTY zone
Cosmoprof Asia 2014 launches the SPOT ON BEAUTY zone

All attendees are invited to visit BOUTIQUE and hand-pick deluxe samples from featured exhibiting brands for a donation to the Hong Kong Breast Cancer Foundation
All attendees are invited to visit BOUTIQUE and
hand-pick deluxe samples from featured exhibiting brands
for a donation to the Hong Kong Breast Cancer Foundation

More than 150 brands are expected to take part covering 1,200 sqm of exhibition space at SPOT ON BEAUTY
More than 150 brands are expected to take part
covering 1,200 sqm of exhibition space at SPOT ON BEAUTY
“Cosmoprof Asia provides a global meeting place and networking platform, and its growth over the years confirms its leading influence in the Beauty sector,” says Duccio Campagnoli, President of BolognaFiere Group and Cosmoprof Asia Limited. The continued growth of the show has contributed to the launch of a new exhibition area Spot On Beauty in 2014 edition.

SPOT ON BEAUTY — The Brand New Product Launch Platform

This new zone is a dedicated platform for innovative finished products from professional beauty, spa and wellness, nail care, hair, cosmetics and personal care segments. Many of the new companies to the show, mainly from the Asia-Pacific region (Japan, Korea and mainland China) but also from Europe and the United States, will be exhibiting in the Spot On Beauty zone, which promises to unveil many brand new, exciting and innovative products. More than 150 brands are expected to take part covering 1,200 sqm of exhibition space.

Located at the Convention Hall at the first level of the Hong Kong Convention & Exhibition Centre, the Spot On Beauty zone is easily accessible from the Harbour Road main entrance. High quality buyers will also be specially invited to Spot on Beauty and be amongst the first to view these new products.

“This exclusive zone offers exhibitors the chance to showcase their latest innovations to influential retail buyers and distributors in the region,” says Michael Duck, Executive Vice President, UBM Asia Ltd.

BOUTIQUE — Beauty Sampling Shop

The Spot On Beauty zone will be complemented by a conceptual project called “BOUTIQUE”. This ‘beauty shop’ will feature deluxe travel-sized samples from selected exhibitors. All attendees of Cosmoprof Asia will be invited to choose from a mix of beauty samples in a personalised gift package, the proceeds of which will go to a local charity, the Hong Kong Breast Cancer Foundation.

“The Hong Kong Breast Cancer Foundation is pleased to be chosen as the charity beneficiary of Cosmoprof Asia’s inaugural BOUTIQUE. The generous support of individuals and organisations is essential to enable the Hong Kong Breast Cancer Foundation to carry out its mission of eliminating the threat of breast cancer through education, support and research and advocacy. We sincerely thank Cosmoprof Asia and all contributors for supporting our efforts,” a spokesperson of the Hong Kong Breast Cancer Foundation said.

Cosmoprof Asia 2014 will be held in Hong Kong from 12- 14 November at the Hong Kong Convention & Exhibition Centre. Trade visitors who register before 17 October will gain free admission to the fair. For more information, please visit the fair website http://www.cosmoprof-asia.com.

Notes to the editors:
Cosmoprof Asia is organised by Cosmoprof Asia Ltd, a joint venture company between UBM Asia Ltd and BolognaFiere Group.
About BolognaFiere Group
http://www.bolognafiere.it
BolognaFiere Group, the world’s leading trade show organizer in the cosmetics, fashion, architecture and building, art and culture sectors, features in its portfolio more than 80 exhibitions, both domestic and international events. SoGeCos S.p.A., as organizer of Cosmoprof Worldwide Bologna (established 1967), the most important beauty meeting point in the world that will take place in Bologna next March 2015 with Cosmopack, has the privilege to work with the beauty industry in the five continents and to monitor new emerging markets where there is a demand for cosmetics products. The international platform offered by Cosmoprof, with its events in Hong Kong (established 1996) and Las Vegas (established 2002), provides a truly global marketplace for the beauty industry where brands can find success.
About UBM Asia Ltd
http://www.ubmasia.com
Owned by UBM plc listed on the London Stock Exchange, UBM Asia is Asia’s leading exhibition organiser and the biggest commercial organiser in mainland China, India and Malaysia. Established with its headquarters in Hong Kong and subsidiary companies across Asia and in the US, UBM Asia has a strong global network of 30 offices and 1,300 staff in 24 major cities. We operate in 20 market sectors with 230 exhibitions and conferences, 23 trade publications, 20 online products for over 1,000,000 quality exhibitors, visitors, conference delegates, advertisers and subscribers from all over the world.
ASIA
UBM Asia Ltd
Amy Ng
+852-2516-1659
amy.ng@ubm.com
Janice Poon
+852-2516-2117
janice.poon@ubm.com
WORLDWIDE
SoGeCos s.p.a – BolognaFiere Group
Mr Paolo Landi
+39-0245-4708-320
paolo.landi@cosmoprof.it
Source: Cosmoprof Asia

Written by asiafreshnews

May 29, 2014 at 5:18 pm

Posted in Uncategorized

RS Components and Allied Electronics Recognise Siemens, Phoenix Contact, Arduino and Schneider Electric with 2014 Global Supplier Awards

leave a comment »

Share with Twitter Share with LinkedIn Share with Repost.us

Four suppliers were recognised for outstanding achievement with awards for performance, service excellence, innovation and partnership

SINGAPORE, May 27, 2014 /PRNewswire/ — RS Components (RS) and Allied Electronics (Allied), the trading brands of Electrocomponents plc (LSE:ECM), the world’s leading high service distributor of electronics and maintenance products, have hosted their first global Supplier Awards to recognise the achievements of selected manufacturers during the past year in four different categories: performance; service excellence; innovation; and partnership. The awards were presented to the four category winners at a celebratory event held at the Hong Kong Sevens rugby tournament from 28-30 March 2014.

Siemens was named as the winner of the Performance Award in recognition of the supplier’s efforts to achieve outstanding sales growth in the last 12 months. Siemens has also worked together with RS and Allied to acquire thousands of new customers, and helped to generate a significant improvement in return on stock.

In the Service Excellence category, electrical engineering and automation manufacturer Phoenix Contact was honoured for attaining the highest delivery accuracy on over 35,000 orders channelled through RS and Allied globally.

The developers of the Arduino open-source electronics prototyping platform took the award for Innovation, not merely for product innovation, but also for their collaborative work with RS and Allied on exclusive delivery, preferential launch quantities, and replenishment lead times. Outstanding technical and marketing support was also a key factor, including video tutorials, blogs, and joint participation at the Maker Faire inventors’ exhibition, all of which contributed to exceptional sales growth on the Arduino range.

The award for Partnership was bestowed to Schneider Electric for working with RS and Allied to develop their largest ever co-operative sales and marketing initiative targeted at customers globally. Schneider is also a strong advocate of the revolutionary new DesignSpark Mechanical 3D modelling software launched by RS and Allied in 2013, utilising the platform to provide sales support to engineers. The company is closely aligned with RS and Allied on their eCommerce strategy.

“We stock around 500,000 products from thousands of suppliers globally, and we aim to foster close relationships with our suppliers to enhance our offer to customers,” commented Phil Dock, Global Head of Product and Supplier Management at Electrocomponents. “We have established these supplier awards to highlight and recognise what can be achieved through successful co-operation globally, and by embracing new ways of engaging with and supporting customers through innovative online resources.”

About RS Components
RS Components and Allied Electronics are the trading brands of Electrocomponents plc, the world’s leading high service distributor of electronics and maintenance products. With operations in 32 countries, we offer around 500,000 products through the internet, catalogues and at trade counters to over one million customers, shipping around 44,000 parcels a day. Our products, sourced from 2,500 leading suppliers, include electronics, automation and control, test and measurement, electrical and mechanical components.
Electrocomponents is listed on the London Stock Exchange and in the last financial year ended 31 March 2013 had revenues of GBP1.24bn.
For more information, please visit the website at http://www.rs-components.com.
Further information is available via these links:
@RSElectronics; @alliedelec; @designsparkRS
RS Components on Linkedin
http://www.linkedin.com/company/rs-components
RS Components on Weibo
http://e.weibo.com/u/3206377000?type=0
Relevant Links:
Electrocomponents plc
http://www.electrocomponents.com
RS Components
http://www.rs-components.com
DesignSpark
http://www.designspark.com
RS Components
Tan Soo Chun
Public Relations Manager – Asia Pacific
Email: soochun.tan@rs-components.com
Telephone: +65-6391-5745
Edelman Public Relations (Singapore)
Yvette Yeo
Manager
Email: yvette.yeo@edelman.com
Telephone: +65-6347-2355
Source: RS Components
Related stocks: LSE:ECM

Written by asiafreshnews

May 29, 2014 at 12:22 pm

Posted in All releases

Thomson Reuters Targets Global Taxation Needs of Japanese Companies with its Award-Winning ONESOURCE(TM) Tax Software and Services

leave a comment »

TOKYO, May 27, 2014 /PRNewswire/ — Japanese multinational companies (MNCs) face tough times in the current market, brought about by increased scrutiny, global tax compliance requirements and the depreciation of the Japanese yen. In response to these challenges, many Japanese MNCs are restructuring their business operations in order to minimize their operating costs. Any such business changes must consider the tax impact and the process of complying with complex international tax laws which are constantly changing.

To help Japanese MNCs address these challenges, Thomson Reuters has established its Tax & Accounting business operations in Japan to provide its award-winning ONESOURCE™ suite of tax software and services. Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals, aims to help Japanese MNCs simplify their global tax compliance processes, creating a competitive advantage and increasing transparency across the whole finance function.

ONESOURCE was recognised as a leader in innovating corporate tax technology by leading tax news and analysis publication International Tax Review and named “America’s Tax Innovator of the Year” consecutively in 2012 and 2013.

“Establishing a presence in the Japanese market is an important step in our strategic expansion in Asia Pacific. Having a dedicated team of tax, accounting, content and technology experts in Japan will ensure that our customers benefit from local and global expertise,” said Charlotte Rushton, managing director, Asia Pacific and EMEA for the Tax & Accounting business of Thomson Reuters.

Governments are increasingly relying on indirect taxes[1] to boost overall tax revenues and fund infrastructure spending. Increased global trade means more indirect taxes such as VAT/GST, customs and excise duties. In a global environment characterised by intense competition, Japanese MNCs have to manage the practicalities of doing business in multiple geographical markets with complex tax compliance laws. ONESOURCE Indirect Tax enables Japanese MNCs to achieve high levels of indirect tax compliance across the world, including complicated multi-level tax regimes such as the US, Brazil, Russia and China.

With compliance comes regulatory reporting. Companies have to effectively manage their tax department workflow and drive their tax and compliance reporting processes across their whole operations. To optimize these processes and provide the group tax team with global visibility, comprehensive project and document management solutions such as the web-based ONESOURCE WorkFlow Manager enable companies to improve control and operational efficiency with secure, remote access from anywhere at any time.

“With a proven track record of successfully helping MNCs worldwide with local and global operations, Thomson Reuters understands the stringent tax and accounting needs of Japanese MNCs. We are strongly positioned to support their global activities with tax software and services that function globally, and enable them to maintain accurate and seamless tax compliance,” said Tony Kinnear, managing director, ASEAN and North Asia, Thomson Reuters.

For more information about the Thomson Reuters Tax & Accounting business in Japan, visit: https://tax.thomsonreuters.com/japan

Note to Editors:

[1] Indirect tax is levied by the government on consumption and expenditure including some stage of the production-distribution process, but not on income or property.
About Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to http://www.thomsonreuters.com.
CONTACT
Pamela Lim
Thomson Reuters
ASEAN and North Asia
+65-6870-3212
pamela.lim@thomsonreuters.com
Source: Thomson Reuters

Written by asiafreshnews

May 29, 2014 at 11:07 am

Squire Sanders and Patton Boggs Announce Agreement to Combine Firms

leave a comment »

— Operating under the name Squire Patton Boggs, the combined firm will offer clients one of the industry’s broadest and deepest practice offerings as part of a truly global platform spanning 45 offices in 21 countries.

WASHINGTON, May 27, 2014 /PRNewswire/ — Squire Sanders and Patton Boggs today announced that their partners have approved a combination of the firms. The combined firm will bring together Squire Sanders’ top ranked global legal platform and Patton Boggs’ preeminent public policy, white collar and other practices to provide clients with unparalleled geographic reach, breadth and depth of practice capabilities and unmatched knowledge in matters where law, government and business intersect.

Logo – http://photos.prnewswire.com/prnh/20140526/91132

Operating under the name Squire Patton Boggs, the firm will consist of approximately 1,600 lawyers spanning 45 offices in 21 countries around the world. This places the firm among the top 25 firms globally in terms of lawyer headcount, and eighth by number of countries where they have offices, as per The American Lawyer 2013 Global 100. The firm will also rank as one of the top 10 largest firms in Washington DC with approximately 280 lawyers and among the largest in the United States with roughly 785 lawyers.

The merger of Squire Sanders and Patton Boggs will result in a broader and deeper client offering, with complementary practice areas and industry expertise that create a catalyst for increased growth. The firm will be characterized by leading practice groups in areas such as corporate, complex litigation, investigations and white collar defense, intellectual property, public policy, regulatory, capital markets, labor & employment, restructuring and insolvency, real estate, sovereign representation, tax, and public and infrastructure finance. The combined firm will offer leading industry experience in sectors including banking and financial services, energy, utilities, insurance, life sciences, healthcare, transportation, technology and telecommunications.

“Today marks an important day in the history of our firm. Patton Boggs is the premier public policy firm in the world, and this combination establishes us as the ‘go-to’ firm for public policy work. We also gain a leading position in the Middle East and several new locations in the United States, while deepening our bench in a number of important practices areas, all of which strengthen our service platform,” said Jim Maiwurm, Chair and Global CEO of Squire Sanders. “Through our discussions we have gained a great deal of respect for the partnership and culture of Patton Boggs. We are very pleased to combine leading global and public policy firms with diverse and strong practices and client bases, strong regional positions and international orientations. Together we will be uniquely positioned to respond to the needs of business clients around the world.”

“Squire Sanders is recognized as a one of the industry’s leading global law firms with practice and industry expertise in key financial markets spanning the Americas, Europe, Asia-Pacific and the Middle East,” said Ed Newberry, Managing Partner of Patton Boggs. “The platform and collective expertise created through this combination provide considerable opportunities to access new markets, engage clients in new ways and attract and retain top talent. I couldn’t be more excited for the future of our firm.”

“Since the time Patton Boggs was founded over 50 years ago we set out to create an innovative firm that brings legal expertise and lobbying know-how to government and business leaders around the world. That firm evolved into an industry game-changer,” said Thomas Hale Boggs, Jr., chairman of Patton Boggs. “Through our combination with Squire Sanders we are doing it again, by bringing together our rich experience with one of the world’s most expansive practice and geographic footprints.”

“Our goal has long been to create a platform that allows our lawyers to serve their clients no matter where in the world their business needs take them. We have made great strides in this regard, and the completion this merger marks another significant milestone that will position us to become even more competitive in an increasingly global marketplace where clients require specialized expertise,” said Squire Sanders Chairman-Elect Mark Ruehlmann, who will become Chair and Global CEO on January 1, 2015, when Jim Maiwurm’s term expires.

The merger is expected to take effect by June 1, 2014.

Source: Squire Patton Boggs

Written by asiafreshnews

May 29, 2014 at 10:56 am

Posted in Uncategorized

Squire Sanders and Patton Boggs Announce Agreement to Combine Firms

leave a comment »

— Operating under the name Squire Patton Boggs, the combined firm will offer clients one of the industry’s broadest and deepest practice offerings as part of a truly global platform spanning 45 offices in 21 countries.

WASHINGTON, May 27, 2014 /PRNewswire/ — Squire Sanders and Patton Boggs today announced that their partners have approved a combination of the firms. The combined firm will bring together Squire Sanders’ top ranked global legal platform and Patton Boggs’ preeminent public policy, white collar and other practices to provide clients with unparalleled geographic reach, breadth and depth of practice capabilities and unmatched knowledge in matters where law, government and business intersect.

Logo – http://photos.prnewswire.com/prnh/20140526/91132

Operating under the name Squire Patton Boggs, the firm will consist of approximately 1,600 lawyers spanning 45 offices in 21 countries around the world. This places the firm among the top 25 firms globally in terms of lawyer headcount, and eighth by number of countries where they have offices, as per The American Lawyer 2013 Global 100. The firm will also rank as one of the top 10 largest firms in Washington DC with approximately 280 lawyers and among the largest in the United States with roughly 785 lawyers.

The merger of Squire Sanders and Patton Boggs will result in a broader and deeper client offering, with complementary practice areas and industry expertise that create a catalyst for increased growth. The firm will be characterized by leading practice groups in areas such as corporate, complex litigation, investigations and white collar defense, intellectual property, public policy, regulatory, capital markets, labor & employment, restructuring and insolvency, real estate, sovereign representation, tax, and public and infrastructure finance. The combined firm will offer leading industry experience in sectors including banking and financial services, energy, utilities, insurance, life sciences, healthcare, transportation, technology and telecommunications.

“Today marks an important day in the history of our firm. Patton Boggs is the premier public policy firm in the world, and this combination establishes us as the ‘go-to’ firm for public policy work. We also gain a leading position in the Middle East and several new locations in the United States, while deepening our bench in a number of important practices areas, all of which strengthen our service platform,” said Jim Maiwurm, Chair and Global CEO of Squire Sanders. “Through our discussions we have gained a great deal of respect for the partnership and culture of Patton Boggs. We are very pleased to combine leading global and public policy firms with diverse and strong practices and client bases, strong regional positions and international orientations. Together we will be uniquely positioned to respond to the needs of business clients around the world.”

“Squire Sanders is recognized as a one of the industry’s leading global law firms with practice and industry expertise in key financial markets spanning the Americas, Europe, Asia-Pacific and the Middle East,” said Ed Newberry, Managing Partner of Patton Boggs. “The platform and collective expertise created through this combination provide considerable opportunities to access new markets, engage clients in new ways and attract and retain top talent. I couldn’t be more excited for the future of our firm.”

“Since the time Patton Boggs was founded over 50 years ago we set out to create an innovative firm that brings legal expertise and lobbying know-how to government and business leaders around the world. That firm evolved into an industry game-changer,” said Thomas Hale Boggs, Jr., chairman of Patton Boggs. “Through our combination with Squire Sanders we are doing it again, by bringing together our rich experience with one of the world’s most expansive practice and geographic footprints.”

“Our goal has long been to create a platform that allows our lawyers to serve their clients no matter where in the world their business needs take them. We have made great strides in this regard, and the completion this merger marks another significant milestone that will position us to become even more competitive in an increasingly global marketplace where clients require specialized expertise,” said Squire Sanders Chairman-Elect Mark Ruehlmann, who will become Chair and Global CEO on January 1, 2015, when Jim Maiwurm’s term expires.

The merger is expected to take effect by June 1, 2014.

Source: Squire Patton Boggs

Written by asiafreshnews

May 29, 2014 at 9:50 am

Posted in Uncategorized

Orient EuroPharma and Debiopharm Group(TM) Announce Their Partnership and the Launch of Pamorelin(R) LA In Singapore

leave a comment »

SINGAPORE and LAUSANNE, Switzerland, May 27, 2014 /PRNewswire/ — Orient EuroPharma Co., Ltd. (Orient EuroPharma) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines with a strong sales network of 360 dedicated and experienced sales representatives and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs along with companion diagnostics jointly announce the signature of a distribution agreement for the commercialization and promotion of Pamorelin® in South East Asia. Today, Orient EuroPharma and Debiopharm announce the launch of Pamorelin® in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin® in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin® will be made available primarily to urologists and oncologists across Singapore.

Mr.JP. Chang, President of Pharmaceutical Business Unit, Orient EuroPharma said that “it is great to cooperate with Debiopharm Group™ for introducing the new drug to South East Asian territories. Orient EuroPharma owns strong connections and an experienced team in the Oncology field; this partnership will provide another therapy option for physicians to treat prostate cancer patients.”

“This collaboration opens up an important new market for our backbone therapy of advanced prostate cancer (locally advanced and metastatic),” said Thierry Mauvernay, Delegate of the Board, Debiopharm Group. “After successful launch in 74 countries, we look forward to bringing Pamorelin® to several South East Asian markets, together with Orient EuroPharma.”

About Pamorelin® LA (active ingredient: triptorelin)
Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month formulations have already been registered in numerous countries and are available under different brand names: Trelstar®, Decapeptyl® and Pamorelin®. The 6-month formulation has been registered and is available in Singapore, Europe and the US.
About Orient EuroPharma
Orient EuroPharma Co., Ltd. (OEP) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines, and a strong sales network of 360 dedicated and experienced sales representatives. Established in 1982, the Orient EuroPharma Group officially started trade in the GTSM in Taiwan in 2003. Main products are pharmaceuticals, cancer drugs, cosmeceuticals, infant and adult nutrition and healthcare products. The Group owns eight subsidiaries located in China, Southeast Asia and United States, and more than 760 employees globally. In 2008, it established Orient PHARMA focusing on new drugs development, which includes a new pharmaceutical plant and has obtained Taiwan FDA PIC/S GMP Certificate in 2011 and U.S. FDA CGMP Certificate in 2013. OEP co-op with NanoCarrier Co. Ltd, and jointly invested in construction of a new Taiwan pharmaceutical plant for injectable cancer drugs in 2012, making it one of the few companies that can vertically integrate drug research and development, manufacture, marketing and channel management. For more information, please visit http://www.oep.com.tw.
About Debiopharm Group™
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of 4 companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments.
Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through
out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information about Debiopharm Group™, please visit: http://www.debiopharm.com
Source: Orient EuroPharma Co., Ltd.

Written by asiafreshnews

May 29, 2014 at 9:47 am